The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Managing insufficient responses to induction therapy prior to autoSCT in MM
Rahul Banerjee, MD, Fred Hutchinson Cancer Center, Seattle, WA, discusses whether patients with multiple myeloma that have achieved a partial response with induction therapy should remain in the induction phase or be advanced to autologous stem cell transplant (autoSCT). Dr Banerjee discusses advantages and disadvantages of each approach, and concludes that, whilst cases should be considered individually, the benefits of progressing to autoSCT outweigh the benefits of prolonging induction. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting/advisory: SparkCures, Sanofi Pasteur, Genentech/Roche, Janssen Oncology, Bristol-Myers Squibb/Celgene, Caribou Biosciences, Pfizer
Research funding: Pack Health
